DAILYPEPTIDE GUIDE
Unstandardized combination

SS-31 + MOTS-c

Elamipretide + MOTS-c

Uncertain or Concerning
Identity

Commercial or common name

SS-31 + MOTS-c. This name is not standardized.

Variants

Reported formulation variants

  • Co-administration and mixed-vial claims
Combination evidence

What the combination shows

No adequate human combination evidence was identified in the static MVP review. Component-level findings do not transfer to the combination.

Regulatory

Status

Unapproved / RUO. No approval is implied by use of a commercial or community name.

Human research

Combination trial status

No validated human combination trial identified

Quality

Stability and compatibility

Compatibility, sterility and stability are not established across marketed variants

Claims

Common marketing claims

  • Mitochondrial support
  • Energy and longevity
Evidence-based conclusion

Bottom line

This named stack should be evaluated as an unstandardized combination. It does not inherit the evidence score of its strongest component.

Individual component evidence

Approved TherapeuticAugust 5, 2026

Elamipretide

SS-31

Barth syndrome · Mitochondrial disease research

Tier 2Approved
Experimental / RUOAugust 5, 2026

MOTS-c

Mitochondrial open reading frame of 12S rRNA-c

Longevity claims · Exercise claims

Tier 3Unapproved / RUO